Intra-Cellular Therapies Inc. (NASDAQ:ITCI) Chairman Sharon Mates sold 11,257 shares of the business’s stock in a transaction that occurred on Friday, January 5th. The stock was sold at an average price of $17.08, for a total value of $192,269.56. Following the sale, the chairman now directly owns 1,099,964 shares in the company, valued at $18,787,385.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Sharon Mates also recently made the following trade(s):

  • On Monday, October 30th, Sharon Mates sold 18,750 shares of Intra-Cellular Therapies stock. The stock was sold at an average price of $15.75, for a total value of $295,312.50.

Intra-Cellular Therapies Inc. (ITCI) traded up $0.13 on Friday, hitting $17.47. The stock had a trading volume of 989,961 shares, compared to its average volume of 443,629. The company has a market capitalization of $953.47, a PE ratio of -7.98 and a beta of 0.72. Intra-Cellular Therapies Inc. has a 1 year low of $7.85 and a 1 year high of $22.67.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.53) EPS for the quarter, meeting analysts’ consensus estimates of ($0.53). The firm had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $0.06 million. Intra-Cellular Therapies had a negative return on equity of 27.40% and a negative net margin of 28,038.35%. The company’s quarterly revenue was up 675.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.70) earnings per share. research analysts expect that Intra-Cellular Therapies Inc. will post -2.13 earnings per share for the current fiscal year.

Several brokerages have weighed in on ITCI. BidaskClub raised Intra-Cellular Therapies from a “strong sell” rating to a “sell” rating in a research note on Friday. ValuEngine cut Intra-Cellular Therapies from a “sell” rating to a “strong sell” rating in a research note on Sunday, December 31st. Zacks Investment Research cut Intra-Cellular Therapies from a “buy” rating to a “hold” rating in a research note on Tuesday, October 17th. Cowen reissued an “outperform” rating and set a $27.00 price objective (up from $20.00) on shares of Intra-Cellular Therapies in a research note on Friday, September 8th. Finally, Canaccord Genuity began coverage on Intra-Cellular Therapies in a research note on Friday, December 15th. They set a “buy” rating and a $31.00 price objective on the stock. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the stock. Intra-Cellular Therapies has a consensus rating of “Buy” and a consensus target price of $25.56.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. bought a new position in shares of Intra-Cellular Therapies during the third quarter valued at approximately $101,000. SG Americas Securities LLC bought a new position in shares of Intra-Cellular Therapies during the second quarter valued at approximately $103,000. Quantbot Technologies LP grew its stake in shares of Intra-Cellular Therapies by 233.1% during the third quarter. Quantbot Technologies LP now owns 8,614 shares of the biopharmaceutical company’s stock valued at $135,000 after buying an additional 6,028 shares during the last quarter. Fred Alger Management Inc. bought a new position in shares of Intra-Cellular Therapies during the second quarter valued at approximately $161,000. Finally, Voya Investment Management LLC grew its stake in shares of Intra-Cellular Therapies by 16.0% during the second quarter. Voya Investment Management LLC now owns 16,911 shares of the biopharmaceutical company’s stock valued at $210,000 after buying an additional 2,338 shares during the last quarter. 74.47% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Intra-Cellular Therapies Inc. (ITCI) Chairman Sells $192,269.56 in Stock” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/05/intra-cellular-therapies-inc-itci-chairman-sells-192269-56-in-stock.html.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).

Insider Buying and Selling by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.